The addition of rivaroxaban to aspirin monotherapy reduces the risk of atherothrombotic events in patients who have experienced an acute coronary syndrome (ACS), but it can also increase those patients’ bleeding risk, according to a study published Feb. 28 in the Journal of the American Heart Association.

A systematic approach to transitioning heart attack patients from the hospital to outpatient care helped the Sanger Heart & Vascular Institute in Charlotte, North Carolina, drop its 30-day readmission and death rates while increasing the likelihood of patients making and keeping follow-up appointments.

Transgender men and women might face an increased risk of cardiovascular ills like MI, stroke and venous thromboembolic events (VTEs) as a result of hormone replacement therapy—an often key aspect of the transitioning process for trans individuals.

An elevated heart rate upon hospital admission has been repeatedly linked to an increased risk of mortality for acute MI patients (AMI), making admission heart rate a key component of risk-stratification equations. But researchers recently found a patient’s heart rate at discharge was an even more powerful predictor of death over three years of follow-up.

High-risk strains of human papillomavirus (HPV)—ones that have been linked to anogenital and oral cancers—might also increase a woman’s risk for developing cardiovascular disease, research out of Seoul, South Korea, suggests.

Just half of Americans know the five common heart attack symptoms—even when presented with the symptoms as “yes” or “no” answers—based on 2017 results from the National Health Interview Survey (NHIS).

A new study of young heart attack sufferers revealed a sobering, albeit unsurprising, finding: More than 90 percent had at least one modifiable risk factor. What’s equally concerning, according to the authors, is the prevalence of most of these risk factors increased over the decade-long study.

Biologic treatment favorably modifies coronary plaque characteristics for patients with severe psoriasis, suggests a study published Feb. 5 in Cardiovascular Research. The findings raise the possibility that the anti-inflammatory drugs can both treat psoriasis and reduce cardiovascular risk.